Skip to Main content Skip to Navigation
Master thesis

Cétuximab dans le traitement du cancer colorectal métastatique réfractaire à l'irinotécan: évaluation de facteurs cliniques prédictifs de réponse

Abstract : Background : The aim was to identify baseline clinical predictive factors of response to cetuximab-irinotecan (CI) in patients with irinotecan-refractory metastatic colorectal cancer. Patients and methods : Retrospective analysis of patients treated between June 2004 and February 2007 with cetuximab (400 mg/m2 week 1 and 250 mg/m subsequent weeks) plus irinotecan (180 mg/m2/2 weeks). Predictive factors of response to cetuximab were identified using univariate and multivariate analyses according to the following baseline available features: demographic data, disease duration, response to prior chemotherapies, irinotecanfree interval, metastatic sites number, and tumoural immunohistochemical EGFR status. Results : A total of 311 patients were analyzed. The objective response rate under CI was 26 %. ln univariate analysis, a prior response to irinotecan, a disease duration >= 24 months, a metastatic disease duration >=18 months, an irinotecan-free interval >= 1.8 months, and no more than one metastatic site were significantly predictive of response to CI. ln multivariate analysis, an independent predictive value was confirmed for prior response to irinotecan (p < 10-3, RR 1.89), disease duration (p = 0.01, RR 1.75), and number ofmetastatic sites (p < 10-2, RR 1.64). EGFR status had no predictive value. Among 35 EGFR-negative patients, 14 (40 %) achieved'an objective response.Conclusion : Prior response to irinotecan and number of metastatic sites are independent predictive factors of response to CI. This study brings further evidence for also treating with cetuximab EGFR-negative patients.
Document type :
Master thesis
Complete list of metadata

Cited literature [47 references]  Display  Hide  Download

https://hal.univ-lorraine.fr/hal-01731900
Contributor : Colette Orange <>
Submitted on : Wednesday, March 14, 2018 - 2:33:24 PM
Last modification on : Friday, October 23, 2020 - 4:38:08 PM
Long-term archiving on: : Tuesday, September 4, 2018 - 6:00:53 AM

File

SCDMED_T_2007_FOURNIER_PEGGY.p...
Files produced by the author(s)

Identifiers

  • HAL Id : hal-01731900, version 1

Citation

Peggy Fournier. Cétuximab dans le traitement du cancer colorectal métastatique réfractaire à l'irinotécan: évaluation de facteurs cliniques prédictifs de réponse. Sciences du Vivant [q-bio]. 2007. ⟨hal-01731900⟩

Share

Metrics

Record views

18

Files downloads

148